Compare KRUS & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRUS | ACRS |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 485.4M | 529.9M |
| IPO Year | 2019 | 2015 |
| Metric | KRUS | ACRS |
|---|---|---|
| Price | $34.96 | $3.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | ★ $62.88 | $10.09 |
| AVG Volume (30 Days) | 193.0K | ★ 3.9M |
| Earning Date | 11-05-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.75 | 69.01 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $282,763,000.00 | $1,683,000.00 |
| Revenue This Year | $16.80 | N/A |
| Revenue Next Year | $17.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.88 | N/A |
| 52 Week Low | $29.69 | $2.10 |
| 52 Week High | $80.84 | $6.60 |
| Indicator | KRUS | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 42.00 | 45.37 |
| Support Level | $33.97 | $3.18 |
| Resistance Level | $41.99 | $4.67 |
| Average True Range (ATR) | 1.77 | 0.25 |
| MACD | -0.13 | 0.11 |
| Stochastic Oscillator | 47.71 | 86.34 |
Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.